Drug Profile
SSR 180711
Alternative Names: SR180711; SSR-180711A; SSR-180711CLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator sanofi-aventis
- Developer Sanofi; sanofi-aventis
- Class Antidementias; Antipsychotics; Heterocyclic bicyclo compounds; Small molecules
- Mechanism of Action Alpha7 nicotinic acetylcholine receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Alzheimer's disease; Schizophrenia
Most Recent Events
- 07 Nov 2007 Pharmacodynamics data from an animal study presented at the 37th Annual Meeting of the Society for Neurosciences (SfN-2007)
- 13 Feb 2007 Phase-I clinical trials in Alzheimer's disease in Europe (PO)
- 13 Feb 2007 Phase-I clinical trials in Schizophrenia in Europe (PO)